去势抵抗性前列腺癌的治疗进展

贾泽鹏; 陈泽宇; 高旭

doi:10.13201/j.issn.1001-1420.2020.04.013

去势抵抗性前列腺癌的治疗进展

- 海军军医大学附属长海医院泌尿外科(上海, 200433)

详细信息

通讯作者: 高旭,E-mail:gaoxu.changhai@foxmail.com

中图分类号: R737.2

收稿日期: 2020-01-09

Progression of medical therapy for castration-resistant prostate cancer

- Department of Urology, Changhai Hospital of Naval Medical University, Shanghai, 200433, China

More Information

Corresponding author: GAO Xu, E-mail: gaoxu.changhai@foxmail.com

Received Date: 09 January 2020

摘要

摘要: 前列腺癌为常见男性实体器官恶性肿瘤,具有较高发病率和死亡率。转移性去势抵抗性前列腺癌(CRPC)是多数前列腺癌患者病情发展的转归,其临床治疗效果及预后较差,中位总生存期不足2年。部分CRPC患者因前期雄激素剥夺治疗或化学治疗发生耐药抵抗,因此制定有效的治疗方案尤为重要。近年临床用于治疗CRPC的新型内分泌药物主要有醋酸阿比特龙、恩扎卢胺及阿帕他胺等,而靶向治疗和免疫治疗等新疗法也在研发中。本文对CRPC治疗现状及进展进行了总结。
- 去势抵抗性前列腺癌 /
- 雄激素剥夺治疗 /
- 阿比特龙 /
- 恩扎卢胺 /
- 靶向治疗
Abstract: Prostate cancer(PCa) is the most common solid neoplasm in men, with high morbidity and mortality. Most PCa progress to castration-resistant prostate cancer(CRPC) with poor clinical outcomes and prognosis. The median overall survival(OS) can be less than 2 years in patients with mCRPC. Strategies to optimize the order of therapeutic regimens are important for CRPC patients, due to drug resistance caused by previous androgen deprivation therapy(ADT) or chemotherapy. This review will provide an overview on the present and future therapies for CRPC, including targeted and immunotherapy, and recent drugs such as abiraterone acetate, enzalutamide and apalutamide, being utilized in clinic.
- castration-resistant prostate cancer /
- androgen deprivation therapy /
- abiraterone /
- enzalutamide /
- targeted therapy

HTML全文

参考文献(45)

[1]	Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[2]	郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28.
[3]	Zeng H,Zheng R,Guo Y,et al.Cancer survival in China,2003-2005:a population-based study[J].Int J Cancer,2015,136(8):1921-1930.
[4]	Lowrance WT,Murad MH,Oh WK,et al.Castration-Resistant Prostate Cancer:AUA Guideline Amendment 2018[J].J Urol,2018,200(6):1264-1272.
[5]	Heidenreich A,Pfister D,Merseburger A,et al.Castration-resistant prostate cancer:where we stand in 2013 and what urologists should know[J].Eur Urol,2013,64(2):260-265.
[6]	Mottet N,Briers E,Santis MD,et al.EAU-EANM-ESTRO-ESUR-SIOG Guidelines on prostate cancer[J].Eur Association Urol,2019.
[7]	Heinlein CA,Chang C.Androgen receptor in prostate cancer[J].Endocr Rev,2004,25(2):276-308.
[8]	Hu R,Denmeade SR,Luo J.Molecular Processes Leading to Aberrant Androgen Receptor Signaling and Castration Resistance in Prostate Cancer[J].Expert Rev Endocrinol Metab,2010,5(5):753-764.
[9]	Knuuttila M,Yatkin E,Kallio J,et al.Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model[J].Am J Pathol,2014,184(8):2163-2173.
[10]	Azad AA,Zoubeidi A,Gleave ME,et al.Targeting heat shock proteins in metastatic castration-resistant prostate cancer[J].Nat Rev Urol,2015,12(1):26-36.
[11]	Wang K,Ruan H,Xu T,et al.Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer[J].Onco Targets Ther,2018,11:3167-3178.
[12]	Robinson D,Van Allen EM,Wu YM,et al.Integrative Clinical Genomics of Advanced Prostate Cancer[J].Cell,2015,162(2):454.
[13]	Mohler JL,Antonarakis ES,Armstrong AJ,et al.Prostate Cancer,NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2019,17(5):479-505.
[14]	Tannock IF,De Wit R,Berry WR,et al.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer[J].N Engl J Med,2004,351(15):1502-1512.
[15]	Yap TA,Pezaro CJ,De Bono JS.Cabazitaxel in metastatic castration-resistant prostate cancer[J].Expert Rev Anticancer Ther,2012,12(9):1129-1136.
[16]	Oudard S,Fizazi K,Sengeløv L,et al.Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer:A Randomized Phase Ⅲ Trial-FIRSTANA[J].J Clin Oncol,2017,35(28):3189-3197.
[17]	Ryan CJ,Smith MR,Fizazi K,et al.Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer(COU-AA-302):final overall survival analysis of a randomised,double-blind,placebo-controlled phase 3 study[J].Lancet Oncol,2015,16(2):152-160.
[18]	Fizazi K,Scher HI,Molina A,et al.Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer:final overall survival analysis of the COU-AA-301 randomised,double-blind,placebo-controlled phase 3 study[J].Lancet Oncol,2012,13(10):983-992.
[19]	Tran C,Ouk S,Clegg NJ,et al.Development of a second-generation antiandrogen for treatment of advanced prostate cancer[J].Science,2009,324(5928):787-790.
[20]	Mccrea E,Sissung TM,Price DK,et al.Androgen receptor variation affects prostate cancer progression and drug resistance[J].Pharmacol Res,2016,114:152-162.
[21]	Shore ND,Chowdhury S,Villers A,et al.Efficacy and safety of enzalutamide versus bicalutamidefor patients with metastatic prostate cancer(TERRAIN):a randomised,double-blind,phase 2 study[J].Lancet Oncol,2016,17(2):153-163.
[22]	Penson DF,Armstrong AJ,Concepcion R,et al.Enzalutamide Versus Bicalutamide in Castration-ResistantProstate Cancer:The STRIVE Trial[J].J Clin Oncol,34(18):2098-2106.
[23]	Scher HI,Fizazi K,Saad F,et al.Increased survival with enzalutamide in prostate cancer after chemotherapy[J].N Engl J Med,2012,367(13):1187-1197.
[24]	Beer TM,Armstrong AJ,Rathkopf D,et al.Enzalutamide in Men With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer:Extended Analysis of the Phase 3 PREVAIL Study[J].Eur Urol,2017,71(2):151-154.
[25]	Hussain M,Fizazi K,Saad F,et al.Enzalutamide in Men with Nonmetastatic,Castration-Resistant Prostate Cancer[J].N Engl J Med,2018,378(26):2465-2474.
[26]	Smith MR,Saad F,Chowdhury S,et al.Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer[J].N Engl J Med,2018,378(15):1408-1418.
[27]	Fizazi K,Shore N,Tammela TL,et al.Darolutamide in Nonmetastatic,Castration-Resistant Prostate Cancer[J].N Engl J Med,2019,28;380(13):1235-1246.
[28]	Clarke N,Wiechno P,Alekseev B,et al.Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer:a randomised,double-blind,placebo-controlled,phase 2 trial[J].Lancet Oncol,2018,19(7):975-986.
[29]	Mateo J,Carreira S,Sandhu S,et al.DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer[J].N Engl J Med,2015,373(18):1697-1708.
[30]	Hussain M,Mateo J,Fizazi K,et al.PROFOUND:Phase Ⅲ study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations[J].ESMO Congress,2019.
[31]	Kelly WK,Halabi S,Carducci M,et al.Randomized,double-blind,placebo-controlled phase Ⅲ trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer:CALGB 90401[J].J Clin Oncol,2012,30(13):1534-1540.
[32]	Barata PC,Cooney M,Mendiratta P,et al.Phase Ⅰ/Ⅱ Study Evaluating the Safety and Clinical Efficacy of Temsirolimus and Bevacizumab in Patients With Chemotherapy Refractory Metastatic Castration-Resistant Prostate Cancer[J].Invest New Drugs,2019,37(2):331-337.
[33]	Fizazi K,Ulys A,Sengelov L,et al.A randomized,double-blind,placebo-controlled phase Ⅱ study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy[J].Ann Oncol,2017,28(11):2741-2746.
[34]	Smith M,De Bono J,Sternberg C,et al.Phase Ⅲ Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer:COMET-1[J].J Clin Oncol,2016,34(25):3005-3013.
[35]	Carver BS,Chapinski C,Wongvipat J,et al.Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer[J].Cancer Cell,2011,19(5):575-586.
[36]	Lin J,Sampath D,Nannini MA,et al.Targeting activated Akt with GDC-0068,a novel selective Akt inhibitor that is efficacious in multiple tumor models[J].Clin Cancer Res,2013,19(7):1760-1772.
[37]	Zhang LS,Lum L.Delivery of the Porcupine Inhibitor WNT974 in Mice[J].Methods Mol Biol,2016,1481:111-117.
[38]	Quinn DI,Tangen CM,Hussain M,et al.Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer(SWOG S0421):a randomised phase 3 trial[J].Lancet Oncol,2013,14(9):893-900.
[39]	Beer TM,Hotte JS,Saad F,et al.Custirsen(OGX-011)Combined With Cabazitaxel and Prednisone Versus Cabazitaxel and Prednisone Alone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel(AFFINITY):A Randomised,Open-Label,International,Phase 3 Trial[J].Lancet Oncol,2017,18(11):1532-1542.
[40]	Kantoff PW,Higano CS,Shore ND,et al.Sipuleucel-T immunotherapy for castration-resistant prostate cancer[J].N Engl J Med,2010,363(5):411-422.
[41]	Eggermont AM,Chiarion SV,Grob JJ,et al.Adjuvantipilimumab versus placebo aftercomplete resection of high-riskstage Ⅲ melanoma(EORTC 18071):a randomised,doublebind phase 3 trial[J].J Clin Oncol,2015,16(5):522-530.
[42]	Beer TM,Kwon ED,Drake CG,et al.Randomized,Double-Blind,Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer[J].J Clin Oncol,2017,35(1):40-47.
[43]	Boudadi K,Suzman DL,Anagnostou V,et al.Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer[J].Oncotarget,2018,9(47):28561-28571.
[44]	Slovin SF,Wang X,Borquez-Ojeda O,et al.Targeting castration resistant prostate cancer(CRPC)with autologous PSMA-directed CAR+ T cells[J].J Clin Oncol,2012,30:TPS4700-TPS4700.
[45]	Junghans RP,Ma QZ,Rathore R,et al.Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer:Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response Prostate[J].Prostate,2016,76(14):1257-1270.